Blood platelet RNA enables the detection of multiple sclerosis

Nik Sol*, Cyra E Leurs*, Sjors GJG In ’t Veld*, Eva M Strijbis, Adrienne Vancura, Markus W Schweiger, Charlotte E Teunissen, Farrah J Mateen†, Bakhos A Tannous, Myron G Best, Thomas Würdinger† and Joep Killestein†

Abstract
Background: In multiple sclerosis (MS), clinical assessment, MRI and cerebrospinal fluid are important in the diagnostic process. However, no blood biomarker has been confirmed as a useful tool in the diagnostic work-up.

Objectives: Blood platelets contain a rich spliced mRNA repertoire that can alter during megakaryocyte development but also during platelet formation and platelet circulation. In this proof of concept study, we evaluate the diagnostic potential of spliced blood platelet RNA for the detection of MS.

Methods: We isolated and sequenced platelet RNA of blood samples obtained from 57 MS patients and 66 age- and gender-matched healthy controls (HCs). 60% was used to develop a particle swarm-optimized (PSO) support vector machine classification algorithm. The remaining 40% served as an independent validation series.

Results: In total, 1249 RNAs with differential spliced junction expression levels were identified between platelets of MS patients as compared to HCs, including EPSTI1, IFI6, and RPS6KA3, in line with reported inflammatory signatures in the blood of MS patients. The RNAs were subsequently used as input for a MS classifier, capable of detecting MS with 80% accuracy in the independent validation series.

Conclusions: Spliced platelet RNA may enable the blood-based diagnosis of MS, warranting large-scale validation.

Keywords: Multiple sclerosis, platelets, biomarker, RNA, diagnostics

Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder affecting the central nervous system. Clinical assessment, magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) analysis play important roles in the diagnostic process. The field of MS biomarker discovery is thriving and the search for precise diagnostic tests continues. So far, no blood-based biomarker for MS has been confirmed. Minimally invasive blood-based biomarkers would complement current MS diagnostics and monitoring.

During the final stages of thrombopoiesis, platelets are loaded with pre-mature messenger RNAs (pre-mRNAs) before being released from the megakaryocyte. As a result, platelets contain a rich RNA repertoire that can change during megakaryocyte development but also during platelet formation and platelet circulation (Figure 1(a)). Especially the change of RNA transcripts during circulation,
possibly achieved by specific splicing queues, is of relevance in the present study. Platelets respond to activating signals from their environment with specific splicing of their pre-mRNAs and potential uptake of RNA from different cell types, leading to a unique and dynamic RNA repertoire.4–6 It has been shown that RNA isolated from tumor-educated platelets, platelets subjected to RNA changes in patients with cancer, may lead to highly accurate identification of traces of the tumor in blood,7 independent of inflammatory conditions.4

Blood platelets are able to participate in inflammatory responses by secreting different cytokines and interact with different cell types, such as leukocytes and vascular cells.6 Furthermore, platelets may be involved in the progression and pathogenesis of MS.5,9 It has been observed that platelets from MS patients exhibit high levels of activation.10–12 Interestingly, in vivo murine studies demonstrated that platelet depletion reduces MS disease severity.12 Furthermore, coagulation in which platelets play a major role, seems to also play a role in the pathogenesis of MS, suggesting that platelets could serve as target for new therapeutic approaches.13 As a result of their involvement in the immune response and potential role in the progression and development of the disease, we hypothesize that blood platelets of MS patients contain a disease-related RNA-signature which could be used as a diagnostic tool (Figure 1(a)).

Results

Platelet collection
Blood was collected from healthy controls (HCs) (n = 66) and MS patients (n = 57) in EDTA-coated Vacutainer tubes. All patients were diagnosed according to the revised McDonald criteria1 and had relapsing remitting MS for at least 10 years. Of the MS patients, 17 were male and 40 were female, resulting in a ratio of 1:2.4 (Table 1 and S1). All 66 HCs were age- and gender-matched. At the time of
blood draw, the disability status of MS patients was examined according to the Kurtzke Expanded Disability Status Scale (EDSS) and an MRI scan was acquired. Although all patients were in clinical remission, 29 of them showed new T2-hyperintense lesions compared to an earlier performed MRI scan (Table 1).

Platelet RNA as a diagnostics tool for MS
Platelet RNA was sequenced and analyzed according to a previously published protocol 14 (Figure 1(b)). Briefly, platelets were isolated from whole blood by differential centrifugation, platelets were lysed, and RNA was isolated. The RNA was subsequently subjected to RNA amplification and prepared for RNA-sequencing on the Illumina platform.

We employed our previously published thromboSeq classification software for algorithm development.4,14 First we randomly selected from the full dataset 17 MS and 19 HCs samples (30% of the total sample size) and assigned those to the training series, employed for biomarker RNA panel selection. Then, the algorithm optimized the biomarker panel towards accurate prediction by a readout of the randomly selected evaluation series (n = 17 MS and n = 20 HCs). This resulted in a total of 1,249 spliced RNAs which were found to be optimal for blood-based MS diagnostics (Table S2). Of this subset, 645 RNAs were increased in platelets of MS patients as compared to HCs, including the RNAs EPSTI1 and IFI6, whereas RPS6KA3 had decreased levels in MS patients as compared to HCs (Table 2; Table S2).

The classification algorithm reached an accuracy of 84% (area under the curve (AUC): 0.87, 95% confidence interval (95%-CI): 0.76-0.99; Figure 2) in the evaluation series. We subsequently locked the threshold parameters of the algorithm prior to validation, employing a separate MS (n = 23) and HCs (n = 27) sample series, who were not included in algorithm development, resulting in an accuracy of 80% (AUC: 0.87 95%-CI: 0.77-0.97, sensitivity: 83%, specificity 78%; Figure 2). Post-hoc leave-one-out cross validation analysis of the training series resulted in accuracy of 86% (AUC: 0.96, 95%-CI: 0.91-1.00; Figure 2). We confirmed the sensitivity of the spliced RNA panel for the detection of MS by randomly selecting other training and evaluation series with similar sample sizes (n = 1000 iterations, median AUC: 0.89, IQR: 0.08), and confirmed the specificity of the spliced RNA panel by randomly shuffling the groups of the individual samples (n = 1000 iterations, median AUC: 0.50, IQR: 0.17).

Discussion
We provide evidence that processes involved in MS result in alterations of platelet RNA profiles. Furthermore, we were able to demonstrate that RNA derived from circulating blood platelets may act as novel blood-based biomarker for MS. Specific splicing of platelet RNA in the presence of tumors has already been proposed in previous studies.4,7,15

Table 1. Patient characteristics.

|                          | Healthy controls (n = 66) | Multiple Sclerosis (n = 57) | P value |
|--------------------------|---------------------------|----------------------------|---------|
| Gender                   |                           |                            |         |
| Male n(%)                | 22 (33)                   | 17 (30)                    | 0.70    |
| Female n(%)              | 44 (67)                   | 40 (70)                    |         |
| Age (mean ± SD, year)    | 46.5 ± 7.4                | 46.6 ± 6.9                 | 0.91    |
| DMT n(%)                 | NA                        | 27 (47)                    |         |
| New T2 lesions n(%)      | NA                        | 29 (51)                    |         |
| EDSS (mean ± SD)         | NA                        | 3.0 ± 0.9                  |         |

Table 2. Top RNAs with differentials spliced junctions.

| Up in MS       | Down in MS |
|----------------|------------|
| 1 EPSTI1       | HBB        |
| 2 DCUN1D4      | AHCYL1     |
| 3 MTND1P23     | RPS6KA3    |
| 4 IFI6         | CDK16      |
| 5 MTND2P28     | ADI1       |
| 6 UBE2L6       | TADA3      |
| 7 MTRNR2L12    | TMED4      |
| 8 MTND4P12     | EFHC1      |
| 9 ATF7IP       | AMPD2      |
| 11 MTATP6P1    | TUBB       |
In the case of MS, platelets appear to play an important and active role in the disease. Platelets seem to not just be involved in inflammatory and immune responses but may also contribute to the pathogenesis of MS.\textsuperscript{10,12,16} Here we show that blood platelets isolated from patients with MS show a distinctive RNA signature potentially of value for blood-based MS diagnostics.

We found 1249 RNA transcripts with differential levels of spliced transcripts. Compared to our previously published work regarding RNA expression levels in platelets this is a high number. Expanding the sample size will give the opportunity to set a more stringent threshold which will lower the amount of transcripts, though maintaining high accuracy. In the top-list of genes with increased expression are several proteins that have shown to play a role in activation of the immune response in MS like EPSTI1 and IFI6.\textsuperscript{17,18} In the top-list of genes with reduced expression RPS6KA3 is of interest, as this gene has been shown to be downregulated in blood from MS patients in remission.\textsuperscript{19}

This study has several drawbacks. First, although we enrolled age- and gender-matched healthy controls, no individuals were included with other autoimmune or neuroinflammatory disease, potentially reducing the diagnostic accuracy. Especially Neuromyelitis Optica (NMO) would be of interest since it can mimic MS and has a different treatment approach. Second, the sample size was still small, potentially resulting in suboptimal algorithm development. Additional samples should be collected and evaluated. To reach true clinical relevance, follow-up studies should also focus on early-stage MS cases and patients presenting with a clinically isolated syndrome to assess the potential for early detection. All patients in the present study displayed a relapsing-remitting disease course. Future studies should include a broad spectrum of MS subtypes. Furthermore, additional studies are needed to gain insight into its ability to potentially predict disease progression, transition from relapsing remitting MS to secondary progressive MS, and DMT response prediction. Third, the platelet isolation method harbors a leukocyte contamination rate of 1-5 leukocytes per 1 million platelets.\textsuperscript{7} Though, we cannot exclude that at least a part of the profile is derived from nucleated blood cells we believe that platelet-leukocyte aggregates, which can be found in MS patients,\textsuperscript{20} would have an even higher mass compared to leukocytes and would therefore be eliminated during the centrifugation steps. Research focused on these aggregates could be of value.

To our knowledge, this is the first study utilizing RNA found in circulating platelets as a blood-based biomarker for distinguishing MS patients from healthy individuals. The technique’s potential
for early diagnosis and treatment-response prediction, however, still need to be assessed in further studies.

Methods

Patients

MS patients participated in a prospective Amsterdam MS cohort study. They were included in this cohort at diagnosis and subsequently followed annually until year six and had additional follow-up at year 11. Patients have been diagnosed with MS according to the revised McDonald criteria 2017 and were relapse-free and without steroid treatment for at least two months (Table 1 and Table S1). All 66 HCs were age- and gender-matched. This study was conducted in accordance with the principles of the Declaration of Helsinki. Approval of sample collection was obtained from the institutional review board and the ethics committee.

Wet- and dry-lab procedures

Blood processing resulting in platelet RNA seq data, and subsequently algorithm development was preformed according to previously described methods. For particle swarm-optimized (PSO) enhanced algorithm development, we applied the predefined settings; libsize correlation between −0.1 and 1.0, FDR between 0.00001 and 1.0, correlated transcripts between 0.5 and 1.0 and ranked transcripts between 200 and all detected transcripts (4,812). We selected the particle (algorithm settings) with best performance in the evaluation series following evaluation of 100 particles during 10 iterations (1000 particles in total).

Acknowledgements

We are thankful to Edward Post, Heleen Verschueren, Francois Rustenberg, and Laurine E. Wedekind for technical support.

Author contributions

N.S., C.E.L., S.G.J.G.I.t.V., M.G.B. and T.W. and J.K. designed the experiments and wrote the manuscript. N. S., C.E.L., E.M.S. C.E.T. and J.K. provided samples and clinical data. N.S., S.G.J.G.I.t., A.V., M.S., M.G.B. and T. W. performed data analyses. F.J.M. and B.A.T. designed experiments and edited the manuscript.

Code availability

The thromboSeq dry-lab pipeline is available via GitHub (https://github.com/MyronBest/thromboSeq_source_code), and is for research purposes only.

Data availability

The raw sequencing data FASTQ-files have been deposited in the NCBI GEO database.

Conflict of Interests

M.G.B. and T.W. are inventors on relevant patent applications. T.W. received funding from Illumina and is shareholder of GRAIL, Inc.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Financial support was provided by European Research Council 713727 and 336540 (T.W.), the Dutch Organisation of Scientific Research 91711366 (T.W.), the Dutch Cancer Society (T.W.), stichting STOPHersentumoren.nl (M.G.B., N.S., T.W.) and stichting MS research (N.S. J.K.).

ORCID iDs

Nik Sol https://orcid.org/0000-0003-1782-1852
J Mateen https://orcid.org/0000-0002-4293-8115

Supplemental Material

Supplemental material for this article is available online.

References

1. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17: 162–173. doi:10.1016/S1474-4422(17)30470-2
2. Teunissen CE, Malekzadeh A, Leurs C, et al. Body fluid biomarkers for multiple sclerosis-the long road to clinical application. Nat Rev Neurol 2015; 11: 585–596. doi:10.1038/nrneurol.2015.173
3. Cecchetti L, Tolley ND, Michetti N, et al. Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events. Blood 2011; 118: 1903–1911. doi:10.1182/blood-2010-12-324517
4. Best MG, Sol N, In ‘T Veld S, et al. Swarm Intelligence-Enhanced detection of Non-Small-Cell lung cancer using Tumor-Educated platelets. Cancer Cell 2017; 32: 238–252.e9. doi:10.1016/j.ccell.2017.07.004
5. Denis MM, Tolley ND, Bunting M, et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell 2005; 122: 379–391. doi:10.1016/j.cell.2005.06.015
6. Koenen RR. The prowess of platelets in immunity and inflammation. Thromb Haemost 2016; 116: 605–612. doi:10.1160/TH16-04-0300
7. Best MG, Sol N, Kooi I, et al. RNA-Seq of tumor-educated platelets enables blood-based pan-cancer,
multiclass, and molecular pathway cancer diagnostics. *Cancer Cell* 2015; 28: 666–676. doi:10.1016/j.ccell.2015.09.018

8. Pankratz S, Bittner S, Kehrel BE, et al. The inflammatory role of platelets: translational insights from experimental studies of autoimmune disorders. *Int J Mol Sci* 2016; 17 doi:10.3390/ijms17101723

9. Sheremata WA, Jy W, Horstman LL, et al. Evidence of platelet activation in multiple sclerosis. *J Neuroinflammation* 2008; 5: 27. doi:10.1186/1742-2094-5-27

10. Behari M and Shrivastava M. Role of platelets in neurodegenerative diseases: a universal pathophysiology. *Int J Neurosci* 2013; 123: 287–299. doi:10.3109/00207454.2012.751534

11. Morel A, Rywaniak J, Bijak M, et al. Flow cytometric analysis reveals the high levels of platelet activation parameters in circulation of multiple sclerosis patients. *Mol Cell Biochem* February 2017; 430: 69–80. doi:10.1007/s11010-017-2955-7

12. Langer HF, Choi EY, Zhou H, et al. Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. *Circ Res* 2012; 110: 1202–1210. doi:10.1161/CIRCRESAHA.111.256370

13. Plantone D, Inglese M, Salvetti M, Koudriavtseva T. A perspective of coagulation dysfunction in multiple sclerosis and in experimental allergic encephalomyelitis. *Front Neurol* 2019; 9: doi:10.3389/FNEUR.2018.01175

14. Best MG, In ’t Veld SGJG, Sol N, et al. RNA sequencing and swarm intelligence–enhanced classification algorithm development for blood-based disease diagnostics using spliced blood platelet RNA. *Nat Protoc* 2019; 14: 1206–1234. doi:10.1038/s41596-019-0139-5

15. Schubert S, Weyrich AS and Rowley JW. A tour through the transcriptional landscape of platelets. *Blood* 2014; 124: 493–502. doi:10.1182/blood-2014-04-512756

16. Wachowicz B, Morel A, Miller E, et al. The physiology of blood platelets and changes of their biological activities in multiple sclerosis. *Acta Neurobiol Exp (Wars)* 2016; 76: 269–281. http://www.ncbi.nlm.nih.gov/pubmed/28094818. Accessed March 23, 2017.

17. Kim Y-H, Lee J-R and Hahn M-J. Regulation of inflammatory gene expression in macrophages by epithelial-stromal interaction 1 (Epsti1). *Biochem Biophys Res Commun* 2018; 496: 778–783. doi:10.1016/j.bbrc.2017.12.014

18. Cervantes-Gracia K and Husi H. Integrative analysis of multiple sclerosis using a systems biology approach. *Sci Rep* 2018; 8: 5633. doi:10.1038/s41598-018-24032-8

19. Achiron A, Zilkha-Falb R, Feldman A, et al. Polymerase-1 pathway activation in acute multiple sclerosis relapse. *Autoimmun Rev* 2018; 17: 1235–1239. doi:10.1016/j.autrev.2018.07.006

20. Dziedzic A and Bijak M. Interactions between platelets and leukocytes in pathogenesis of multiple sclerosis. *Adv Clin Exp Med* 2019; 28: 277–285. doi:10.17219/acem/83588